Market Overview

UPDATE: Piper Jaffray Upgrades Watson Pharmaceuticals to Overweight on Synergies, Generics Value

Related WPI
Watson Pharma Buys Uteron Pharma SA
UPDATE: Goldman Sachs Downgrades Watson Pharmaceuticals to Neutral on Limited Upside

Piper Jaffray raised its rating on Watson Pharmaceuticals (NYSE: WPI) from Neutral to Overweight and increased its price target from $77 to $103.

Piper Jaffray noted, "With favorable competitive dynamics for an extended period likely for Concerta, Adderall XR (AXR) and Lidoderm, plus attractive synergies from the Actavis purchase and optionality on other generic opportunities (e.g. Intuniv, OxyContin), we believe WPI's current one-year forward P/E of 11x (on our EPS estimate of $8.22) is sustainable. In that context, we believe the risk/reward profile for WPI shares is attractive. We are upgrading WPI to an Overweight from a Neutral and raising our price target to $103 from $77, reflecting upward revisions to our estimates and a higher multiple."

Watson Pharmaceuticals closed at $87.71 on Thursday.

Latest Ratings for WPI

Jan 2013Goldman SachsDowngradesBuyNeutral
Nov 2012Credit SuisseMaintainsOutperform
Nov 2012PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for WPI
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (WPI)

View Comments and Join the Discussion!